Filing Flows › Maxcyte (MXCT) › Q2 2025
Maxcyte (MXCT) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 6, 2025
Maxcyte (MXCT) reported revenue of $8.5M for the second quarter 2025 (Q2 2025), -18% from a year earlier and -18% from the quarter before. Operating margin was -167.2%, net loss $12.4M (145.3% of revenue).
Maxcyte, Q2 2025: revenue $8.5M (-18% year over year), operating margin -167.2%, net loss $12.4M, operating cash flow −$9.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.5M | -18% | -18% |
| Operating profit | −$14.2M | — | — |
| Net earnings | −$12.4M | — | — |
| Operating cash flow | −$9.9M | — | — |
What changed
Revenue was $8.5M in Q2 2025, down 18% year over year and down 18% from the previous quarter. Product sales was the largest line at 62% of revenue. Licenses lost $2.5M year over year (down 46%), 132% of the total change.
Gross margin was 82.1%, down 3.6 points from a year earlier. Operating costs exceeded revenue by $14.2M, an operating margin of -167.2%. Operating expenses grew 1% against a revenue fall of 18%. The fastest-growing cost line was Research & development (+12%). The quarter ended with a net loss of $12.4M, wider than the previous quarter's $10.3M loss.
Operating cash flow was −$9.9M. Non-cash charges added back $1.1M of depreciation and amortization and $3.5M of share-based compensation. Working capital and other items used $2.1M. Capital expenditures of $584K exceeded it, leaving free cash flow of −$10.4M.
Questions
What was Maxcyte's revenue in the second quarter 2025?
Maxcyte (MXCT) reported revenue of $8.5M for the second quarter 2025 (Q2 2025), -18% from a year earlier and -18% from the quarter before.
Was Maxcyte profitable in the second quarter 2025?
Operating loss was $14.2M (-167.2% of revenue) and net loss $12.4M.
Source: Maxcyte 10-Q on SEC EDGAR.